Trial Profile
A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jan 2021 Results assessing clinical benefit with sunitinib using the combined data from two studies (NCT00428597 and NCT01525550), published in the Targeted Oncology.
- 29 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Jan 2018 Brazil, Estonia, Netherlands, Poland, Portugal, were the planned locations as per European Clinical Trials Database record.